Hormone Therapy News

Recently postmenopausal women with elevated blood pressure but no other CVD risk factors were more likely to develop white matter lesions 14 years later, regardless of short-term hormone therapy use, data show.

Growing interest in male contraceptive options in the wake of the Dobbs decision and current abortion laws have spurred increased attention in development of a transdermal gel for men to block sperm production.

Use of menopausal hormone therapy among midlife active-duty servicewomen in the U.S. is twice as high as the general population but lower than women veterans, suggesting those who may derive the most benefit from HT are not receiving it.

Less than 0.1% of adolescents in the United States identified as transgender or gender diverse and received puberty blockers or gender-affirming hormones, according to study findings published this week in JAMA Pediatrics.

SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with advanced breast cancer resistant to hormone therapy, according to study results presented at San Antonio Breast Cancer Symposium.

Cardiovascular disease risks vary depending on the type of menopausal hormone therapy combinations and administration methods used, according to a nationwide trial published in The BMJ.

Short-term exposure to hormone therapy started within 3 years of menopause was not associated with long-term cognitive impairment or benefit, according to data from the KEEPS Continuation study.

Patients using testosterone replacement therapy for at least 3 months may have an increased risk for ACL injuries, according to recently published data.

DENVER — Bilateral oophorectomy was common during gender-affirming hysterectomy and associated with younger age, prior testosterone use and male identity, according to study results presented at the ASRM Scientific Congress & Expo.